Meta-analysis of statins in chronic kidney disease: who benefits?

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Vascular disease management in advanced chronic kidney disease (CKD) using lipid-lowering therapies has yielded suboptimal results.
• Understanding the differential efficacy of statins across various stages of kidney function is crucial for optimizing patient care.

Purpose of the Study:

• To investigate the effectiveness of statin therapy in reducing cardiovascular events and mortality across different stages of chronic kidney disease (CKD).
• To stratify statin efficacy based on kidney function classification, including CKD stages 3, 4, 5, dialysis, and renal transplant recipients.

Main Methods:

• A comprehensive meta-analysis was conducted, synthesizing data from randomized controlled trials comparing statins versus placebo.
• Participant data were specifically analyzed for subgroups: CKD stage 3 (eGFR 30-59 ml/min), CKD stage 4 (eGFR 15-29 ml/min), CKD stage 5/dialysis (eGFR <15 ml/min), and renal transplant patients.
• Key outcomes assessed included major adverse cardiovascular events (MACE), cardiovascular death, and all-cause mortality (ACM).

Main Results:

• Statins significantly reduced MACE and ACM in CKD stage 3 patients (19,386 participants).
• A probable reduction in MACE was observed in CKD stage 4 patients (2,565 participants), though cardiovascular and all-cause mortality data were limited.
• No convincing evidence of benefit was found for any outcome in CKD stage 5/dialysis patients (7,051 participants), and statins did not significantly reduce MACE or ACM in functioning renal transplant recipients (2,102 participants).

Conclusions:

• Statins are indicated for CKD stage 3 and likely beneficial for CKD stage 4.
• Current evidence does not support the use of statins in CKD stage 5/dialysis patients.
• The efficacy of statins in renal transplant recipients is probable but requires further investigation due to limited participant numbers in trials.